A case analysis of liver injury induced by gefitinib
10.12173/j.issn.1005-0698.202312074
- VernacularTitle:1例使用吉非替尼致肝损伤的病例分析
- Author:
Pei XU
1
;
Mi ZHANG
;
Xin XIONG
;
Lu HUANG
Author Information
1. 宜昌市中心人民医院药学部/三峡大学药物制剂研究所(湖北宜昌 443000)
- Keywords:
Gefitinib;
Liver injury;
Adverse drug reaction
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(1):111-115
- CountryChina
- Language:Chinese
-
Abstract:
A 68-year-old male patient with malignant left lung tumor was treated with gefitinib(250 mg,po,qd)for 29 days.Liver function test results showed AST 310 U·L-1,ALT 493 U·L-1,AKP 100 U·L-1,TBil 18 μmol·L-1,GGT 60 U·L-1,INR 1.81.Several liver function indicators of the patient showed abnormal,which was consistent with the clinical manifestations of moderate liver injury.The liver function index of the patient improved after the doctor adopted the suggestion of clinical pharmacists to protect the liver.Clinical pharmacists made a comprehensive and dynamic assessment of the patient's condition,analyzed the correlation between the patient's liver injury and gefitinib,and judged that the patient's liver injury was likely caused by gefitinib.Clinical pharmacists analyzed the drug use of a blind trial patient,proposed the follow-up treatment plan,and discussed the blind trial drugs,which provided references for clinical safe and rational drug use and had important reference significance.
